Artivion, Inc. (AORT) Stock

Healthcare · Medical Devices · Member of Other US Stocks

Artivion, Inc. (AORT) closed at USD 21.87 on 2026-10-15, a change of -51.4 % over the past year, with a market capitalization of USD 1.06B.

Artivion, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Artivion, Inc. key figures

Previous close

USD 21.87 (2026-10-15)

1-year change

-51.4 %

Market cap

USD 1.06B

Enterprise value

USD 1.39B

P/E ratio (trailing)

-311.14

P/E ratio (forward)

29.11

EPS (trailing)

-0.07

EPS (forward)

0.75

PEG ratio

643.75

Price to book

2.38

Revenue growth

11.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.72

Employees

1,800

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Artivion, Inc.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Artivion, Inc. and compare it with other stocks.